Skip to content

Released Mar 18, 2021, before the open

10-K filed Mar 18, 2021, 77 days after period end · 0001193125-21-085777

Q4 2020 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$251.00Kderivedno prior Q4 2019 on file+40.2% vs Q3 2020
Net Income-$20.76Mderivedno prior Q4 2019 on fileN/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$20,779,000—
Operating Cash Flowderived-$10,655,000N/M
Free Cash Flowderived-$18,144,000N/M
Margins · derived
Operating margin-8278.5%
Net margin-8270.1%

What the release said

The release

Same quarter

MetricQ4 2020derived from reported figuresQ4 2019derived from reported figures
Revenue$251.00K—
Net Income-$20.76M—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR